Laurus Labs Ltd.

LAURUSLABS

₹620.65

1.9% (11.6)

Market Cap

₹33,453 Cr.

P/E

167.05

About

Laurus Labs Limited is a leading player in the global pharmaceutical industry, offering a wide range of Active Pharma Ingredients (API), Generic Finished dosage forms (FDF), and Contract Research serv… Read more

Laurus Labs Limited is a leading player in the global pharmaceutical industry, offering a wide… Read more

Low

385

52W Range

High

646

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

ROE

Asset turnover is responsible for roe increase over last 10 years
Sales Growth

Sales of the company has grown at a good pace
Balance Sheet Strength

Balance sheet of the company is strong. it shouldnt have solvency or liquidity issues
Capex vs ROCE

Company has made significant capex which might be affecting its roce
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Debt

Company might have issues servicing its debt
Share price

Share price has increased over last 10 years but more due to rerating
Working Capital

Company has significant working capital which is dragging its roce and roe
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

API Break-Up

Operational Metrics

US DMF Filings (.)
Source
Number of ANDA's Filed in Europe
Source
Number of ANDA's Approved in Europe
Source
Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Number of ANDA's Approved by Canada
Source
Number of ANDA's Filed in Canada
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

Neogen Chemicals Ltd.
HLE Glascoat Ltd.
Tatva Chintan Pharma Chem Ltd.
Chemcon Speciality Chemicals Ltd.

Customers

Aurobindo Pharma Ltd.
Cipla Ltd.
Natco Pharma Ltd.
Strides Pharma Science Ltd.
Sun Pharmaceutical Industries Ltd.
Aspen Pharmacare Limited
Mylan

Showing 5 of 7

FAQs on Laurus Labs Ltd. Business

What does Laurus Labs do?

Laurus Labs Limited offers a wide range of Active Pharma Ingredients (API), Generic Finished dosage forms (FDF), and Contract Research services globally, focusing on areas like anti-retroviral, Hepatitis C, and Oncology drugs through continuous innovation.

Who are the competitors of Laurus Labs?

Laurus Labs major competitors are Neuland Laboratories, Alivus Life Sciences, Granules India, AMI Organics, Aarti Pharmalabs, Shilpa Medicare, Supriya Lifescience.
Market Cap of Laurus Labs is ₹32,814 Crs.
While the median market cap of its peers are ₹10,133 Crs.

Is Laurus Labs financially stable compared to its competitors?

Laurus Labs seems to be less financially stable compared to its competitors.
Altman Z score of Laurus Labs is 6.12 and is ranked 6 out of its 8 competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Superstar Favourites

Companies where superstar investors like Rakesh Jhunjhunwala, Asish Kacholia have invested

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release		Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation		Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Apr Jun Jul Sep Dec	Jan Mar Jun Sep Dec	Mar Jun Sep Nov	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Dec
Conference Call		Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Laurus Labs Ltd.

Divis vs Laurus - SOIC

Why LaurusLabs bought a significant stake in a cell and gene therapy startup ImmunoACT? - Tar

Laurus | An Emerging Moat? - SOIC

View the discussion on ValuePickr

What’s up with Laurus Labs? - StockEdge

Approval of First Long Acting Injectable HIV Treatment on Laurus Labs - Dr Midhun

Some Red Flags For Laurus Labs - Deepak Kapur

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Laurus Labs Ltd.